Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Lignende værker

• Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes
  af: Battise, Dawn M.
  Udgivet: (2014)
• Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
  af: Kelmenson, Daniel A., et al.
  Udgivet: (2017)
• Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
  af: Wilding, J P H, et al.
  Udgivet: (2013)
• Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
  af: Schernthaner, Guntram, et al.
  Udgivet: (2013)
• Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus()
  af: Qiu, Rong, et al.
  Udgivet: (2014)